BeckmanCoulter公司推出新型分子诊断样本制备平台

 
 
一种新型样本制备平台能够为核酸分离、定量、标准化和下游分析准备提供新的解决方案。

这种平台叫做Vidiera NsP，是以Beckman Coulter公司(Fullerton, CA, USA)的Biomek自动化和诊断试管处理工艺为基础的，专门设计用于满足医院和参考实验室对分子学检测不断增长的需求。

Vidiera可以用于病毒学和病理学的分子学诊断，还可以整合进Beckman Coulter的Vidiera NsD核酸样本检测系统。Vidiera NsP能够被用于制备分子诊断实验室目前进行的绝大多数下游分析设备，而Vidiera NsD能够允许在一间房间内把分析前检测功能进行集中。Vidiera NsP将会向高度复杂的诊断实验室推广。

“我们公司的新型Vidiera系列产品，将我们的专业特长应用于临床诊断和科研实验室自动化，有利于不断增长的分子学检测方法。”Bruce Wallace如此解释说，他是Beckman Coulter公司核酸检测部门的副总裁。“这条产品线是我们生物医学检测持续发展战略的一个明确范例，证明了我们雄厚的专业优势将会为诊断实验室带来全新的解决方案。”

Beckman Coulter在全球范围内已经安装了超过200,000套系统，把生物医学检测范围从尖端医学科研和临床实验室扩大至实验室诊断和床边检测。

Sample Preparation for Molecular Diagnostics
 
A new sample preparation platform represents a new solution for nucleic acid isolation, quantification, normalization, and reaction set-up for downstream assay analysis.

Called Vidiera NsP, the platform is based on the Biomek automation and diagnostic primary tube-handling technologies of Beckman Coulter (Fullerton, CA, USA) and is specifically designed to meet the growing need for molecular testing in hospital and reference laboratories.

Vidiera can be used for molecular diagnostic applications in virology and pathology and can be integrated with Beckman Coulter’s Vidiera NsD nucleic sample detection system. Vidiera NsP can be used for setting-up reactions for most major downstream analytical instruments that molecular diagnostic laboratories have today, while Vidiera NsD enables labs to centralize pre-analytic functions in one room and to streamline the process. Vidiera NsP will be marketed to high-complexity diagnostic laboratories.

“Our new Vidiera products bring together our expertise in clinical diagnostics and research laboratory automation to benefit the growing field of molecular testing,” explained Bruce Wallace, vice president, nucleic acid testing business, Beckman Coulter.
“This product line is a clear example of our biomedical testing continuum strategy and demonstrates the advantage our broad range of expertise gives us in bringing new solutions to the diagnostic workplace.”

Beckman Coulter has more than 200,000 installed systems around the world that span the biomedical testing continuum from pioneering medical research and clinical trials to laboratory diagnostics and point-of-care testing.